<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01649297</url>
  </required_header>
  <id_info>
    <org_study_id>1276.10</org_study_id>
    <secondary_id>2012-000905-53</secondary_id>
    <nct_id>NCT01649297</nct_id>
  </id_info>
  <brief_title>A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy</brief_title>
  <official_title>A Randomised, Double Blind, Placebo Controlled, Parallel Group Efficacy and Safety Study of Oral Administration of Empagliflozin Twice Daily Versus Once Daily in Two Different Daily Doses Over 16 Weeks as add-on Therapy to a Twice Daily Dosing Regimen of Metformin in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate the efficacy and safety of two doses (high and low)
      of empagliflozin as add-on therapy to metformin in patients with type 2 diabetes mellitus
      (T2DM) and insufficient glycaemic control. Both doses may be given once daily or split to a
      twice daily dosage. This results in 4 different dosage regimens of empagliflozin (high dose
      once daily or split vs. low dose once daily or split). This is done to evaluate whether a
      twice daily dose regimen of empagliflozin results in a loss of efficacy relative to once
      daily dosing when given on top of metformin background therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c (Glycosylated Haemoglobin) Change From Baseline at Week 16</measure>
    <time_frame>Baseline and 16 weeks</time_frame>
    <description>Change from baseline in HbA1c (%) after 16 weeks of treatment. The term 'baseline' refers to the last observation prior to the first intake of any randomised study medication.
Means provided are the adjusted means.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasting Plasma Glucose (FPG) Change From Baseline at Week 16</measure>
    <time_frame>Baseline and 16 weeks</time_frame>
    <description>Change from baseline in FPG (mg/dL) after 16 weeks of treatment. The term 'baseline' refers to the last observation prior to the first intake of any randomised study medication.
Means provided are the adjusted means.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">983</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>empagliflozin (high dose qd)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive Empagliflozin high dose once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>empagliflozin (high dose bid)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive Empagliflozin high dose split twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>empagliflozin (low dose qd)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive Empagliflozin low dose once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>empagliflozin (low dose bid)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive Empagliflozin low dose split twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive placebo matching Empagliflozin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients receive placebo matching empagliflozin (low dose qd)</description>
    <arm_group_label>empagliflozin (high dose qd)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients receive placebo matching empagliflozin (low dose bid)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients receive placebo matching Empagliflozin (high dose qd)</description>
    <arm_group_label>empagliflozin (high dose bid)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients receive placebo matching Empagliflozin (high dose qd)</description>
    <arm_group_label>empagliflozin (low dose bid)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients receive placebo matching Empagliflozin (high dose qd)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>empagliflozin (low dose qd)</intervention_name>
    <description>Patients receive Empagliflozin low dose once daily</description>
    <arm_group_label>empagliflozin (low dose qd)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients receive placebo matching empagliflozin (low dose qd)</description>
    <arm_group_label>empagliflozin (low dose bid)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients receive placebo matching empagliflozin (low dose bid)</description>
    <arm_group_label>empagliflozin (low dose qd)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients receive placebo matching Empagliflozin (high dose bid)</description>
    <arm_group_label>empagliflozin (high dose qd)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients receive placebo matching Empagliflozin (high dose bid)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients receive placebo matching empagliflozin (low dose qd)</description>
    <arm_group_label>empagliflozin (high dose bid)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients receive placebo matching empagliflozin (low dose bid)</description>
    <arm_group_label>empagliflozin (high dose qd)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients receive placebo matching Empagliflozin (high dose bid)</description>
    <arm_group_label>empagliflozin (low dose bid)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients receive placebo matching empagliflozin (low dose qd)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients receive placebo matching empagliflozin (low dose bid)</description>
    <arm_group_label>empagliflozin (high dose bid)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients receive placebo matching Empagliflozin (high dose bid)</description>
    <arm_group_label>empagliflozin (low dose qd)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin (high dose qd)</intervention_name>
    <description>Patients receive Empagliflozin high dose once daily</description>
    <arm_group_label>empagliflozin (high dose qd)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>empagliflozin (high dose bid)</intervention_name>
    <description>Patients receive Empagliflozin high dose split twice daily</description>
    <arm_group_label>empagliflozin (high dose bid)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients receive placebo matching Empagliflozin (high dose qd)</description>
    <arm_group_label>empagliflozin (low dose qd)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>empagliflozin (low dose bid)</intervention_name>
    <description>Patients receive Empagliflozin low dose split twice daily</description>
    <arm_group_label>empagliflozin (low dose bid)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. confirmed diagnosis of T2DM

          2. Glycated hemoglobin (HbA1c) &gt;=7.0 and &lt;=10/0% at Visit 1

          3. Metformin therapy (at least 1500 mg/day, BID)

          4. age&gt;=18 at Visit 1

          5. body mass index &lt;=45 kg/m2

        Exclusion criteria:

          1. estimated creatinine clearance rate (eCCr) &lt;60 ml/min (Cockcroft-Gault formula)
             screening and/or run-in

          2. a confirmed glucose level &gt;240 mg/dl (&gt;13.3 mmol/L) after an overnight fast during
             placebo run-in
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1276.10.11036 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Florence</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.11049 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.11040 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lomita</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.11033 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.11002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rancho Cucamonga</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.11050 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.11015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>West Hills</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.11012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Norwalk</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.11047 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.11010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.11005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Davie</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.11004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.11051 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.11009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oakland Park</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.11044 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.11030 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dunwoody</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.11027 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.11020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Elwood</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.11001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.11048 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sterling Heights</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.11058 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.11055 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Edison</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.11011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.11035 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>North Myrtle Beach</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.11041 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.11018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.11043 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.11017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kettering</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.11022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fleetwood</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.11003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Johnson City</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.11042 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.11013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.11026 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.11031 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.11034 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.11028 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pearland</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.11029 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.11016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Port Orchard</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.11024 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.61002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wollongong</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.61001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.20008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.20005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.20010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.20002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bathurst</city>
        <state>New Brunswick</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.20001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.20007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Corunna</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.20006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sarnia</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.20004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Drummondville</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.20003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Point Claire</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.20009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Victoriaville</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.37203 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pärnu</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.37201 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.37202 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.37204 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Viljandi County</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.33002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aire sur l'Adour</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.33003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bischheim</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.33009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bourg des Comptes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.33014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bourges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.33007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Broglie</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.33001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mont de Marsan</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.33008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.33006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saint Vinecnt de Tyrosse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.33011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Segre</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.33004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.99501 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.99502 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.99503 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.99504 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.99505 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.99506 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.49001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aschaffenburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.49006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.49007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.49005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.49004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.49002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nürnberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.49003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rehlingen-Siersburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.50201 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guatemala Ciudad</city>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.50203 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guatemala Ciudad</city>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.50204 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guatemala Ciudad</city>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.50205 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guatemala Ciudad</city>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.50202 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Quetzaltenango Ciudad</city>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.39004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Arenzano (GE)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.39003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.39007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Catanzaro</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.39009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Catanzaro</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.39002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.39006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.39001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.39008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.39005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.37102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Daugavpils</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.37104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ogre</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.37101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.37103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tukums</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.37003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.37004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.37002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Klaipeda</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.37001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.52001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ciudad de Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.52002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ciudad de Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.52003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Durango</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.52005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pachuca</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.52004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tijuana</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.64001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.64002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Greenlane East Auckland NZ</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.48001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.48002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.48008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gizycko</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.48005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.48006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.48004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.48003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.70001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.70002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.70003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.70004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.70005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.70007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.70008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.70009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.27004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Paarl</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.27003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Parow</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.27006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Plumstead, Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.27001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.27005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.27002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Somerset West</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.34005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.34001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.34003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.34002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Les Borges del Camp</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.34004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sant Adria del Besos</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.34006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vic</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.38002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.38007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.38001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.38004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1276.10.38005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Georgia</country>
    <country>Germany</country>
    <country>Guatemala</country>
    <country>Italy</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Turkey</country>
  </removed_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/</url>
  </link>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 23, 2012</study_first_submitted>
  <study_first_submitted_qc>July 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2012</study_first_posted>
  <results_first_submitted>June 26, 2015</results_first_submitted>
  <results_first_submitted_qc>June 26, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 23, 2015</results_first_posted>
  <disposition_first_submitted>March 27, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>March 27, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 24, 2014</disposition_first_posted>
  <last_update_submitted>June 26, 2015</last_update_submitted>
  <last_update_submitted_qc>June 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Empa 12.5mg BID</title>
          <description>Oral administration of Empagliflozin (Empa) 12.5 mg twice daily (BID)</description>
        </group>
        <group group_id="P2">
          <title>Empa 25mg QD</title>
          <description>Oral administration of Empagliflozin (Empa) 25 mg once daily (QD)</description>
        </group>
        <group group_id="P3">
          <title>Empa 5mg BID</title>
          <description>Oral administration of Empagliflozin (Empa) 5 mg twice daily (BID)</description>
        </group>
        <group group_id="P4">
          <title>Empa 10mg QD</title>
          <description>Oral administration of Empagliflozin (Empa) 10 mg once daily (QD)</description>
        </group>
        <group group_id="P5">
          <title>Placebo</title>
          <description>Oral administration of Placebo tablets matching empagliflozin 25 mg, 10 mg, 5 mg, and 2.5 mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="219">randomised</participants>
                <participants group_id="P2" count="218">randomised</participants>
                <participants group_id="P3" count="219">randomised</participants>
                <participants group_id="P4" count="220">randomised</participants>
                <participants group_id="P5" count="107">randomised</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="205"/>
                <participants group_id="P2" count="205"/>
                <participants group_id="P3" count="202"/>
                <participants group_id="P4" count="201"/>
                <participants group_id="P5" count="103"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="19"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="13"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non compliant with Protocol</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient withdrawal (not due to AE)</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>For other reason</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full Analysis Set: FAS being defined as all patients randomised, treated with at least one dose of study drug, had a baseline Glycosylated Haemoglobin (HbA1c) and at least one on-treatment HbA1c assessment.</population>
      <group_list>
        <group group_id="B1">
          <title>Empa 12.5mg BID</title>
          <description>Oral administration of Empagliflozin (Empa) 12.5 mg twice daily (BID)</description>
        </group>
        <group group_id="B2">
          <title>Empa 25mg QD</title>
          <description>Oral administration of Empagliflozin (Empa) 25 mg once daily (QD)</description>
        </group>
        <group group_id="B3">
          <title>Empa 5mg BID</title>
          <description>Oral administration of Empagliflozin (Empa) 5 mg twice daily (BID)</description>
        </group>
        <group group_id="B4">
          <title>Empa 10mg QD</title>
          <description>Oral administration of Empagliflozin (Empa) 10 mg once daily (QD)</description>
        </group>
        <group group_id="B5">
          <title>Placebo</title>
          <description>Oral administration of Placebo tablets matching empagliflozin 25 mg, 10 mg, 5 mg, and 2.5 mg</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="215"/>
            <count group_id="B2" value="214"/>
            <count group_id="B3" value="215"/>
            <count group_id="B4" value="214"/>
            <count group_id="B5" value="107"/>
            <count group_id="B6" value="965"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.6" spread="9.9"/>
                    <measurement group_id="B2" value="58.2" spread="10.2"/>
                    <measurement group_id="B3" value="58.8" spread="9.8"/>
                    <measurement group_id="B4" value="58.5" spread="10.8"/>
                    <measurement group_id="B5" value="57.9" spread="11.2"/>
                    <measurement group_id="B6" value="58.2" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="95"/>
                    <measurement group_id="B4" value="106"/>
                    <measurement group_id="B5" value="52"/>
                    <measurement group_id="B6" value="445"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="123"/>
                    <measurement group_id="B2" value="114"/>
                    <measurement group_id="B3" value="120"/>
                    <measurement group_id="B4" value="108"/>
                    <measurement group_id="B5" value="55"/>
                    <measurement group_id="B6" value="520"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>HbA1c (Glycosylated Haemoglobin) Change From Baseline at Week 16</title>
        <description>Change from baseline in HbA1c (%) after 16 weeks of treatment. The term 'baseline' refers to the last observation prior to the first intake of any randomised study medication.
Means provided are the adjusted means.</description>
        <time_frame>Baseline and 16 weeks</time_frame>
        <population>Full Analysis Set (FAS) is the basis for the intention-to-treat analysis. FAS with last observation carried forward (LOCF) imputation is used as the primary method of accounting for missing data.
Values after the patient started rescue medication were excluded from analysis (and imputed with an LOCF procedure).</population>
        <group_list>
          <group group_id="O1">
            <title>Empa 12.5mg BID</title>
            <description>Oral administration of Empagliflozin (Empa) 12.5 mg twice daily (BID)</description>
          </group>
          <group group_id="O2">
            <title>Empa 25mg QD</title>
            <description>Oral administration of Empagliflozin (Empa) 25 mg once daily (QD)</description>
          </group>
          <group group_id="O3">
            <title>Empa 5mg BID</title>
            <description>Oral administration of Empagliflozin (Empa) 5 mg twice daily (BID)</description>
          </group>
          <group group_id="O4">
            <title>Empa 10mg QD</title>
            <description>Oral administration of Empagliflozin (Empa) 10 mg once daily (QD)</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Oral administration of Placebo tablets matching empagliflozin 25 mg, 10 mg, 5 mg, and 2.5 mg</description>
          </group>
        </group_list>
        <measure>
          <title>HbA1c (Glycosylated Haemoglobin) Change From Baseline at Week 16</title>
          <description>Change from baseline in HbA1c (%) after 16 weeks of treatment. The term 'baseline' refers to the last observation prior to the first intake of any randomised study medication.
Means provided are the adjusted means.</description>
          <population>Full Analysis Set (FAS) is the basis for the intention-to-treat analysis. FAS with last observation carried forward (LOCF) imputation is used as the primary method of accounting for missing data.
Values after the patient started rescue medication were excluded from analysis (and imputed with an LOCF procedure).</population>
          <units>percentage of HbA1c</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="214"/>
                <count group_id="O3" value="215"/>
                <count group_id="O4" value="213"/>
                <count group_id="O5" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.83" spread="0.05"/>
                    <measurement group_id="O2" value="-0.72" spread="0.05"/>
                    <measurement group_id="O3" value="-0.66" spread="0.05"/>
                    <measurement group_id="O4" value="-0.64" spread="0.05"/>
                    <measurement group_id="O5" value="-0.22" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The primary objective was to test the non-inferiority of empagliflozin 5 mg BID versus empagliflozin 10 mg QD, and non-inferiority of empagliflozin 12.5 mg BID versus empagliflozin 25 mg QD, assuming a non-inferiority margin of 0.35%</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Null hypotheses for non-inferiority:
H10: Mean change from baseline in HbA1c (%) after 16 weeks of treatment with empagliflozin 5 mg twice daily ≥ mean change from baseline in HbA1c (%) after 16 weeks of treatment with empagliflozin 10 mg once daily + 0.35%
H20: Mean change from baseline in HbA1c (%) after 16 weeks of treatment with empagliflozin 12.5 mg twice daily ≥ mean change from baseline in HbA1c (%) after 16 weeks of treatment with empagliflozin 25 mg once daily + 0. 35%</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The two non-inferiority hypotheses H10 and H20 were tested using the Hochberg procedure in order to control the family-wise type I error at 0.025 (one-sided).</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA: Treatment, geographical region, renal function (screening eGFR [MDRD] value)- fixed effects and baseline HbA1c- linear covariate.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.02</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.07</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.16</ci_lower_limit>
            <ci_upper_limit>0.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary objective was to test the non-inferiority of empagliflozin 5 mg BID versus empagliflozin 10 mg QD, and non-inferiority of empagliflozin 12.5 mg BID versus empagliflozin 25 mg QD, assuming a non-inferiority margin of 0.35%</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Null hypotheses for non-inferiority:
H10: Mean change from baseline in HbA1c (%) after 16 weeks of treatment with empagliflozin 5 mg twice daily ≥ mean change from baseline in HbA1c (%) after 16 weeks of treatment with empagliflozin 10 mg once daily + 0.35%
H20: Mean change from baseline in HbA1c (%) after 16 weeks of treatment with empagliflozin 12.5 mg twice daily ≥ mean change from baseline in HbA1c (%) after 16 weeks of treatment with empagliflozin 25 mg once daily + 0. 35%</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The two non-inferiority hypotheses H10 and H20 were tested using the Hochberg procedure in order to control the family-wise type I error at 0.025 (one-sided).</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA: Treatment, geographical region, renal function (screening eGFR [MDRD] value)- fixed effects and baseline HbA1c- linear covariate.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.11</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.07</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.26</ci_lower_limit>
            <ci_upper_limit>0.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Superiority of once daily dose of empagliflozin (10 mg and 25 mg) versus placebo and superiority of twice daily dose of empagliflozin (5 mg and 12.5 mg) versus placebo in reducing HbA1c after 16 weeks of treatment was tested in an exploratory manner, to demonstrate assay sensitivity against placebo at 0.05 level (two-sided).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA: Treatment, geographical region, renal function (screening eGFR [MDRD] value)- fixed effects and baseline HbA1c- linear covariate.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.61</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.09</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.79</ci_lower_limit>
            <ci_upper_limit>-0.44</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Superiority of once daily dose of empagliflozin (10 mg and 25 mg) versus placebo and superiority of twice daily dose of empagliflozin (5 mg and 12.5 mg) versus placebo in reducing HbA1c after 16 weeks of treatment was tested in an exploratory manner, to demonstrate assay sensitivity against placebo at 0.05 level (two-sided).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA: Treatment, geographical region, renal function (screening eGFR [MDRD] value)- fixed effects and baseline HbA1c- linear covariate.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.50</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.09</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.68</ci_lower_limit>
            <ci_upper_limit>-0.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Superiority of once daily dose of empagliflozin (10 mg and 25 mg) versus placebo and superiority of twice daily dose of empagliflozin (5 mg and 12.5 mg) versus placebo in reducing HbA1c after 16 weeks of treatment was tested in an exploratory manner, to demonstrate assay sensitivity against placebo at 0.05 level (two-sided).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA: Treatment, geographical region, renal function (screening eGFR [MDRD] value)- fixed effects and baseline HbA1c- linear covariate.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.44</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.09</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.62</ci_lower_limit>
            <ci_upper_limit>-0.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Superiority of once daily dose of empagliflozin (10 mg and 25 mg) versus placebo and superiority of twice daily dose of empagliflozin (5 mg and 12.5 mg) versus placebo in reducing HbA1c after 16 weeks of treatment was tested in an exploratory manner, to demonstrate assay sensitivity against placebo at 0.05 level (two-sided).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA: Treatment, geographical region, renal function (screening eGFR [MDRD] value)- fixed effects and baseline HbA1c- linear covariate.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.42</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.09</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.60</ci_lower_limit>
            <ci_upper_limit>-0.25</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Plasma Glucose (FPG) Change From Baseline at Week 16</title>
        <description>Change from baseline in FPG (mg/dL) after 16 weeks of treatment. The term 'baseline' refers to the last observation prior to the first intake of any randomised study medication.
Means provided are the adjusted means.</description>
        <time_frame>Baseline and 16 weeks</time_frame>
        <population>FAS with LOCF has been used for FPG analyses</population>
        <group_list>
          <group group_id="O1">
            <title>Empa 12.5mg BID</title>
            <description>Oral administration of Empagliflozin (Empa) 12.5 mg twice daily (BID)</description>
          </group>
          <group group_id="O2">
            <title>Empa 25mg QD</title>
            <description>Oral administration of Empagliflozin (Empa) 25 mg once daily (QD)</description>
          </group>
          <group group_id="O3">
            <title>Empa 5mg BID</title>
            <description>Oral administration of Empagliflozin (Empa) 5 mg twice daily (BID)</description>
          </group>
          <group group_id="O4">
            <title>Empa 10mg QD</title>
            <description>Oral administration of Empagliflozin (Empa) 10 mg once daily (QD)</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Oral administration of Placebo tablets matching empagliflozin 25 mg, 10 mg, 5 mg, and 2.5 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Plasma Glucose (FPG) Change From Baseline at Week 16</title>
          <description>Change from baseline in FPG (mg/dL) after 16 weeks of treatment. The term 'baseline' refers to the last observation prior to the first intake of any randomised study medication.
Means provided are the adjusted means.</description>
          <population>FAS with LOCF has been used for FPG analyses</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
                <count group_id="O2" value="214"/>
                <count group_id="O3" value="213"/>
                <count group_id="O4" value="213"/>
                <count group_id="O5" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.7" spread="2.0"/>
                    <measurement group_id="O2" value="-22.7" spread="2.0"/>
                    <measurement group_id="O3" value="-21.2" spread="2.0"/>
                    <measurement group_id="O4" value="-17.6" spread="2.0"/>
                    <measurement group_id="O5" value="-0.2" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-3.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.8</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-9.0</ci_lower_limit>
            <ci_upper_limit>1.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-5.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.8</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-10.4</ci_lower_limit>
            <ci_upper_limit>0.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Superiority of once daily dose of empagliflozin (10 mg and 25 mg) versus placebo and superiority of twice daily dose of empagliflozin (5 mg and 12.5 mg) versus placebo in reducing FPG after 16 weeks of treatment was tested in an exploratory manner, to demonstrate assay sensitivity against placebo at 0.05 level (two-sided)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA:'Treatment','geographical region','renal function'(screening(eGFR)[MDRD]value)-fixed effects and 'baseline HbA1c',baseline FPG-linear covariate</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-27.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-34.2</ci_lower_limit>
            <ci_upper_limit>-20.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Superiority of once daily dose of empagliflozin (10 mg and 25 mg) versus placebo and superiority of twice daily dose of empagliflozin (5 mg and 12.5 mg) versus placebo in reducing FPG after 16 weeks of treatment was tested in an exploratory manner, to demonstrate assay sensitivity against placebo at 0.05 level (two-sided)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA:'Treatment','geographical region','renal function'(screening(eGFR)[MDRD]value)-fixed effects and 'baseline HbA1c',baseline FPG-linear covariate</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-22.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-29.2</ci_lower_limit>
            <ci_upper_limit>-15.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Superiority of once daily dose of empagliflozin (10 mg and 25 mg) versus placebo and superiority of twice daily dose of empagliflozin (5 mg and 12.5 mg) versus placebo in reducing FPG after 16 weeks of treatment was tested in an exploratory manner, to demonstrate assay sensitivity against placebo at 0.05 level (two-sided)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA:'Treatment','geographical region','renal function'(screening(eGFR)[MDRD]value)-fixed effects and 'baseline HbA1c',baseline FPG-linear covariate</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-21.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-27.7</ci_lower_limit>
            <ci_upper_limit>-14.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Superiority of once daily dose of empagliflozin (10 mg and 25 mg) versus placebo and superiority of twice daily dose of empagliflozin (5 mg and 12.5 mg) versus placebo in reducing FPG after 16 weeks of treatment was tested in an exploratory manner, to demonstrate assay sensitivity against placebo at 0.05 level (two-sided)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA:'Treatment','geographical region','renal function'(screening(eGFR)[MDRD]value)-fixed effects and 'baseline HbA1c',baseline FPG-linear covariate</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-17.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-24.1</ci_lower_limit>
            <ci_upper_limit>-10.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>16 weeks + 1 week follow-up</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Empa 12.5mg BID</title>
          <description>Oral administration of Empagliflozin (Empa) 12.5 mg twice daily (BID)</description>
        </group>
        <group group_id="E2">
          <title>Empa 25mg QD</title>
          <description>Oral administration of Empagliflozin (Empa) 25 mg once daily (QD)</description>
        </group>
        <group group_id="E3">
          <title>Empa 5mg BID</title>
          <description>Oral administration of Empagliflozin (Empa) 5 mg twice daily (BID)</description>
        </group>
        <group group_id="E4">
          <title>Empa 10mg QD</title>
          <description>Oral administration of Empagliflozin (Empa) 10 mg once daily (QD)</description>
        </group>
        <group group_id="E5">
          <title>Placebo</title>
          <description>Oral administration of Placebo tablets matching empagliflozin 25 mg, 10 mg, 5 mg, and 2.5 mg</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="219"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="220"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Macular degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Parotid gland enlargement</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Salivary gland pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Exostosis of jaw</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Biliary adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="219"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="220"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="218"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="219"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="220"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI’s intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

